Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
OMI Environmental Solutions Inc.®, a company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, implemented SteraMist technology into four ...
read more
Wednesday, September 25, 2019
Catalent and Minerva Neurosciences have entered into a commercial supply agreement for roluperidone, an investigational compound from Minerva, for symptoms of schizophrenia.
read more
Verastem Oncology has received U.S. Food and Drug Administration (FDA) approval for Copiktra (duvelisib) capsules.
read more
Catalent has signed an agreement with ViralClear to work on the development of a potential treatment for adults with advanced COVID-19.
read more
Wednesday, February 12, 2020
Catalent has signed an agreement with Zumutor Biologics to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors.
read more
Wednesday, March 29, 2023
Catalent announced the launch of the ProteoSuiteSM Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into clinical trials.
read more
Catalent Pharma Solutions welcomed the announcement by OPKO Health that the FDA has accepted for review OPKO’s New Drug Application for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s proprietary ...
read more
Monday, February 26, 2018
Catalyst Biosciences announced they have entered into a manufacturing agreement with AGC Biologics for the process transfer and commercial scale cGMP manufacturing of CB 2679d.
read more
Catalyst Biosciences has announced the appointment of Charles Democko as Senior Vice President, Regulatory Affairs.
read more
Monday, December 19, 2016
Catalyst Biosciences has secured all rights to the manufacturing process for marzeptacog alfa (activated) (formerly known as CB 813d) from Wyeth LLC, a wholly-owned subsidiary of Pfizer. Marzeptacog alfa (activated) is a next-generation Factor VIIa ...
read more
Catalyst Clinical Research, a provider of clinical research services, announced a strategic acquisition of Aptus Clinical to expand the geographic reach of the two companies, and to enhance patient access to advanced, life-changing therapies.
read more
Friday, February 16, 2024
Catalyst Clinical Research announced that Nik Morton, the company's president and COO, assumed its CEO role on 12 February 2024. Mr. Morton joined Catalyst as its COO in 2022. Mr. Morton moved into his new position while Nick Dyer, Catalyst's former ...
read more
Catawba Research, a global clinical research organization (CRO), has named Julie Arnold as its vice president of project management. The continued addition of top-tier talent to the leadership team exemplifies Catawba Research’s unwavering commitment...
read more
Tuesday, February 06, 2024
Catawba Research, a global clinical research organization (CRO), announced a new collaboration with Bingli Inc., which provides AI-guided diagnosis, disease management, and navigation for patients and healthcare providers.
read more
Catawba Research, a full-service contract research organization (CRO) announced Andy Silverman, Ph.D., has joined its leadership team as its chief operating officer (COO).
read more